Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) ...(ll not said Joe Burnett Vice President ...)

Date:9/21/2009

ll not," said Joe Burnett, Vice President of Volcano. "PROSPECT is designed to show that not all coronary disease is the same. Some lesions may progress rapidly and lead to events. Others may remain stable for years. In the same way that biopsies are performed to stage different types of cancers, PROSPECT will determine the ability of VH IVUS to help cardiologists risk-stratify various types of atherosclerotic plaques. We hope that the data from PROSPECT will be able to identify which lesions are likely to be aggressive and lead to events, and which lesions are more likely to be stable and left alone. This may be the first step to determining which patients will benefit from early intervention and one day reduce the number of sudden heart attacks."

Breakfast Symposium

Volcano is hosting a breakfast symposium entitled "Right Patient, Right Lesion, Right Way: Healthcare reform demands precise, targeted interventions ... angiography alone is not enough." This session will focus on the importance of using more precise tools to identify which patients and lesions benefit most from stenting, and once identified, using precise imaging tools to ensure these stents are placed optimally. Speakers for this session include Morton Kern, M.D., William French, M.D. and Hoang Thai, M.D. The event will be held in room 123 of the Moscone Center on Wednesday, September 23. Breakfast will be served at 6:30 AM followed by the symposium at 7:00 AM.

Evening Symposium

Volcano will host an evening symposium entitled, "Imaging Matters! Identifying high risk patients and optimizing PCI." The symposium will include late breaking results from PROSPECT, FAME and other clinical studies. The first session of the symposium, entitled, "Can imaging help identify at-risk vulnerable plaques and patients before catastrophe (or those not at risk)," will feature presentations from Patrick W. Serruys, M.D., Gary S. Mintz, M.D., Gregg
'/>"/>

SOURCE Volcano Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
11. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System